Premium
Genomewide Association Studies in Pharmacogenomics
Author(s) -
McInnes Gregory,
Yee Sook Wah,
Pershad Yash,
Altman Russ B.
Publication year - 2021
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.2349
Subject(s) - pharmacogenomics , genome wide association study , biobank , genetic association , pharmacogenetics , computational biology , biology , bioinformatics , genetics , single nucleotide polymorphism , genotype , gene
The increasing availability of genotype data linked with information about drug‐response phenotypes has enabled genomewide association studies (GWAS) that uncover genetic determinants of drug response. GWAS have discovered associations between genetic variants and both drug efficacy and adverse drug reactions. Despite these successes, the design of GWAS in pharmacogenomics (PGx) faces unique challenges. In this review, we analyze the last decade of GWAS in PGx. We review trends in publications over time, including the drugs and drug classes studied and the clinical phenotypes used. Several data sharing consortia have contributed substantially to the PGx GWAS literature. We anticipate increased focus on biobanks and highlight phenotypes that would best enable future PGx discoveries.